It may not be much of a surprise that narcissistic CEOs of pharmaceutical companies will make bold choices, such as adopting radically new technology. That idea remains true, despite a lengthy correction to a paper that supports it.
The paper, “CEO Narcissism, Audience Engagement, and Organizational Adoption of Technological Discontinuities,” in Administrative Science Quarterly, found support for the following hypothesis:
Continue reading Paper on narcissistic CEOs earns big correction
An investigation into the work of Olivier Voinnet by The EMBO Journal has led to another two retractions and three more corrections for the high-profile plant scientist, now suspended from the CNRS for two years.
According to the authors, Voinnet was responsible for some of the errors; all papers have been questioned on PubPeer.
The EMBO J, the flagship publication of the European Molecular Biology Organization, posted four notices earlier today and told Retraction Watch that the notice for the fifth paper would be posted by tomorrow.
This latest round brings our count for Voinnet up to Continue reading EMBO investigation yields two more retractions and three corrections for Voinnet
Olivier Voinnet — a plant researcher who was recently suspended for two years from the Centre national de la recherche scientifique (CNRS) after an investigation by ETH Zurich and CNRS found evidence of misconduct — has issued his second retraction and two more corrections.
PNAS posted the retraction earlier this week for a 2006 article after an inspection of the raw data revealed “errors” in study images. Authors confirmed the issues in some figures and revealed “additional mounting mistakes” in others.
Voinnet has promised to issue retractions and corrections for every study that requires them. These latest notices bring our tally up to nine corrections, two retractions and one Expression of Concern.
Continue reading Voinnet notches second retraction, two more corrections
High-profile plant biologist Olivier Voinnet has been suspended for two years from the Centre national de la recherche scientifique (CNRS) following the results of two investigations that revealed a number of issues in his publication record.
An investigation at ETH Zurich found that the scientist “breached his duty of care in the handling of figures as well as in his supervisory duties as a research director.”
Another investigation at CNRS, where Voinnet also works as a researcher, also found “the existence of deliberate chart/diagram manipulations” — while not “fabrication,” these breaches “amount to scientific misconduct,” according to a press release about the report.
The ETH committee uncovered multiple errors, from the “mere confusion of correct and incorrect figures” to “the ‘beautification’ of figures,” but said that it was not scientific misconduct, according to ETH guidelines:
There may be some deeply rooted issues in the work of high-profile plant biologist Olivier Voinnet, biology department research director at ETH in Zurich. Corrections have continued to pile up months after his work was hit with a barrage of criticism on PubPeer. We’ve tracked a total of seven corrections over the past five months (not including the April retraction of a 2004 paper in The Plant Cell). One of the corrected papers also received an Expression of Concern this week.
Collectively, the corrected papers have accumulated more than 1200 citations.
In January, Voinnet said he planned to correct multiple papers, after receiving “an anonymous email.”
One of the recent corrections we found is for a 2003 article in The Plant Journal, “An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virus,” which details using proteins from a tomato virus to help alter gene expression. The study has been cited 862 times, according to Thomson Scientific’s Web of Knowledge. Here’s the correction notice, posted June 8:
The Lancet Oncology is correcting a 2011 article about the cancer risks of radiofrequency electromagnetic fields, such as those from cell phones, to clarify information about potential conflicts of interest for one of the experts who was involved in its preparation.
The assessments appeared as a monograph for the International Agency for Research on Cancer (IARC).
However, after the 2011 paper “Carcinogenicity of radiofrequency electromagnetic fields” appeared, a reader raised allegations of conflicts of interest among its participants, which sparked a reconsideration of their disclosures.
The correction concerns the conflicts of interest for Niels Kuster of the Swiss Federal Institute of Technology in Zurich, also a board member of the non-profit IT’IS foundation.
Kuster told Retraction Watch he disclosed everything upfront:
Continue reading Lancet Oncology updates conflicts of interest statement for cancer-cell phone paper
A team of biologists that retracted two papers after being “unable to replicate some of the results obtained by the first author of the paper” has now issued a correction to fix references to the two sunk publications.
The corrected paper is a review in the Journal of Virology — known there as a Gem — which discusses how viruses use the membranes of endoplasmic reticulum (ER) to replicate.
The two retractions were not signed by their first author, Riccardo Bernasconi, who won the STSBC-Roche Diagnostics award for one of the papers in 2012. The correction carries all three authors’ names, including Bernasconi’s (as second author).
Here’s more from the correction for “How Viruses Hijack the ERAD Tuning Machinery”: Continue reading Biology team with two retractions now correcting references to nixed papers
The story about Olivier Voinnet, a high-profile plant biologist whose work has fallen under scrutiny, continues to build momentum. Late last week, Voinnet’s employer and one of his funders announced they were investigating his work, and one of the peer reviewers of a soon-to-be-retracted paper has made her original report public.
Here’s the statement from CNRS, which funds Voinnet: Continue reading Investigations into Voinnet’s work announced; critic publishes original peer review
A 2014 Cancer Cell paper became the subject of an erratum in January 2015, shortly after PubPeer members began criticizing the data. However, many issues brought up by commenters weren’t addressed in the correction notice, including a figure that might be two experiments spliced together to look like one.
The paper, led by Guido Franzoso at Imperial College London, claims that a new cancer drug called DTP3 kills myeloma cells “without causing any toxic side effects,” according to a press release from the school. Guido Franzoso is the founder of Kesios Therapeutics, a drug company which is set to begin clinical trials on DTP3.
The correction indicates that Western blots were cropped badly, which omitted several panels discussed in the text, while an “extra time point” was included accidentally. An antibody was also omitted from the description of the procedure.
PubPeer commenters have noticed additional issues, such as a criticism of figure 3D, which were not included or changed in this correction.
Here’s the correction for “Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors”: Continue reading Cancer Cell issues big correction over “incorrectly cropped” figures, other issues
Swiss researchers have retracted an abstract in Clinical Neurophysiology because only one of them actually knew about the paper — and what he submitted had “several mistakes.”
The abstract, about electric impulses in the brain of comatose patients, originally appeared as a poster at the June 2014 joint meeting of multiple Swiss neuroscience societies. It was submitted by first author Alexandre Simonin, who lists his affiliation as the University Hospital of Lausanne, a Swiss hospital.
The meeting proceedings ran in the October issue of Clinical Neurophysiology. Besides the issues of authorship and errors, the notice also says the abstract “potentially conflicts with another publication,” suggesting the data might have already appeared in a paper.
Here’s the notice for “P02. Predicting the outcome of post-anoxic comatose patients based on single-trial EEG analysis”: Continue reading Neuro journal pulls comatose brain abstract due to “several mistakes”